AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11218025 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive degeneration
Number of subjects: 43
Study 11218025 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of disc height classified from MR images
Number of subjects: 43
Study 11218025 — intervention group
Group type: EXPERIMENTAL
Intervention: First sign of disc degeneration (moderate loss of nucleus signal)
Number of subjects: 43
Study 11218025 — intervention group
Group type: EXPERIMENTAL
Intervention: Progress of degeneration
Number of subjects: 43
Study 9362381 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa (IFN‐alpha) treatment
Number of subjects: 90
Study 9362381 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 90
Study 1391264 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN with lipids
Number of subjects: 17
Study 1391264 — intervention group
Group type: COMPARATOR
Intervention: Glucose group (control)
Number of subjects: 17
Study 4010919 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulant group (no bed rest for 24h)
Number of subjects: 352
Study 4010919 — intervention group
Group type: COMPARATOR
Intervention: Bed rest group (confined to bed for 24h)
Number of subjects: 352
Study 30650569 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous first-aid training (32%)
Number of subjects: 1000
Study 30650569 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported confidence in subway safety
Number of subjects: 1000
Study 30650569 — intervention group
Group type: EXPERIMENTAL
Intervention: Socio-demographic characteristics (female, lower income, unmarried)
Number of subjects: 1000
Study 30650569 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct fire-related health response knowledge
Number of subjects: 1000
Study 29332752 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-modal mobilization
Number of subjects: 68
Study 29332752 — intervention group
Group type: COMPARATOR
Intervention: Routine physiotherapy
Number of subjects: 68
Study 26333526 — intervention group
Group type: EXPERIMENTAL
Intervention: Kiosk-based health communication intervention
Number of subjects: 450
Study 26333526 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 450
Study 24796334 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed minimal extracorporeal circulation (MECC)
Number of subjects: 20
Study 24796334 — intervention group
Group type: COMPARATOR
Intervention: Conventional open extracorporeal circulation (CECC)
Number of subjects: 20
Study 22315495 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/day imatinib
Number of subjects: 100
Study 22315495 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg/day imatinib
Number of subjects: 100
Study 22315495 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib C(min) > 1165 ng/mL on Day 29
Number of subjects: 100
Study 22315495 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib C(min) levels
Number of subjects: 100
Study 19821004 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% ethanolamine oleate after gelatin sponge administration (group E)
Number of subjects: 82
Study 19821004 — intervention group
Group type: COMPARATOR
Intervention: Fibrin glue and iodized oil (group F)
Number of subjects: 82
Study 17585023 — intervention group
Group type: EXPERIMENTAL
Intervention: P125 (1.00 g protein x kg(‐1) x d(‐1))
Number of subjects: 36
Study 17585023 — intervention group
Group type: EXPERIMENTAL
Intervention: P94 (0.75 g protein x kg(‐1) x d(‐1))
Number of subjects: 36
Study 17585023 — intervention group
Group type: EXPERIMENTAL
Intervention: P63 (0.50 g protein x kg(‐1) x d(‐1))
Number of subjects: 36
Study 17585023 — intervention group
Group type: EXPERIMENTAL
Intervention: Males (independent of protein intake)
Number of subjects: 36
Study 17585023 — intervention group
Group type: COMPARATOR
Intervention: Age and dietary protein effect on serum albumin concentrations
Number of subjects: 36
Study 16128940 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking exercise (G1)
Number of subjects: 383
Study 16128940 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise (G2)
Number of subjects: 383
Study 14566492 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia (5-10 mg.kg(‐1).h(‐1))
Number of subjects: 36
Study 14566492 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anesthesia (0.5%-1.0%)
Number of subjects: 36
Study 10458256 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced compassion videotape
Number of subjects: 210
Study 10458256 — intervention group
Group type: COMPARATOR
Intervention: Standard videotape
Number of subjects: 210
Study 7790243 — intervention group
Group type: EXPERIMENTAL
Intervention: AHFX‐S: 1.6 Gy/fraction, twice daily (6‐h interval), 5 days/week, total dose of 67.2 Gy/42 fractions/6 weeks
Number of subjects: 75
Study 7790243 — intervention group
Group type: COMPARATOR
Intervention: AFX‐C: 1.8 Gy/fraction/day, 5 daily fractions/week to 54 Gy/30 fractions/6 weeks, total dose of 70.5 Gy/41 fractions/6 weeks
Number of subjects: 75
Study 7790243 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 75
Study 2154086 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril plus sodium restriction (low salt group)
Number of subjects: 25
Study 2154086 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril plus hydrochlorothiazide (diuretic group)
Number of subjects: 25
Study 7272394 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused attention on one channel
Number of subjects: 0
Study 7272394 — intervention group
Group type: EXPERIMENTAL
Intervention: Divided attention
Number of subjects: 0
Study 7272394 — intervention group
Group type: EXPERIMENTAL
Intervention: High stimulation rate and/or difficult targets
Number of subjects: 0
Study 7272394 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow negative shift (SNS)
Number of subjects: 0
Study 31582554 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous carriers of the fibrinogen gamma gene (FGG) rs2066865
Number of subjects: 4374
Study 31582554 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer patients homozygous for the FGG variant
Number of subjects: 4374
Study 31582554 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer patients homozygous carriers of FGG
Number of subjects: 4374
Study 31582554 — intervention group
Group type: COMPARATOR
Intervention: Cancer patients without risk alleles
Number of subjects: 4374
Study 31582554 — intervention group
Group type: EXPERIMENTAL
Intervention: Synergistic effect of rs2066865 and active cancer
Number of subjects: 4374
Study 31385737 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Psychological Therapy (IPT) for Treatment-Resistant Schizophrenia (TRS)
Number of subjects: 48
Study 31385737 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Psychological Therapy (IPT) for Nontreatment Resistant Schizophrenia (NTRS)
Number of subjects: 48
Study 31385737 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) for Nontreatment Resistant Schizophrenia (NTRS)
Number of subjects: 48
Study 31385737 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) for Treatment-Resistant Schizophrenia (TRS)
Number of subjects: 48
Study 27465911 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g soy protein with 66 mg isoflavone (SPI)
Number of subjects: 200
Study 27465911 — intervention group
Group type: COMPARATOR
Intervention: 15 g soy protein alone (SP)
Number of subjects: 200
Study 26088581 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management program intervention
Number of subjects: 140
Study 26088581 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed group (Control)
Number of subjects: 140
Study 23651878 — intervention group
Group type: COMPARATOR
Intervention: Placebo (positive expectation)
Number of subjects: 24
Study 23651878 — intervention group
Group type: COMPARATOR
Intervention: Nocebo (negative expectation)
Number of subjects: 24
Study 23651878 — intervention group
Group type: COMPARATOR
Intervention: Neutral (control)
Number of subjects: 24
Study 23651878 — intervention group
Group type: EXPERIMENTAL
Intervention: MedON (with antiparkinsonian medication)
Number of subjects: 24
Study 23651878 — intervention group
Group type: EXPERIMENTAL
Intervention: MedOFF (without antiparkinsonian medication)
Number of subjects: 24
Study 21824940 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlebotomy (diagnostic blood loss)
Number of subjects: 17676
Study 20031889 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group received education and counseling about ACS symptoms and actions required
Number of subjects: 3522
Study 20031889 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 3522
Study 20031889 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3522
Study 16533495 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic approach to study tactile sense regarding surface roughness
Number of subjects: 0
Study 15471991 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mg daily dose of aspirin
Number of subjects: 128
Study 15471991 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg daily dose of aspirin
Number of subjects: 128
Study 15471991 — intervention group
Group type: EXPERIMENTAL
Intervention: 650 mg daily dose of aspirin
Number of subjects: 128
Study 15471991 — intervention group
Group type: EXPERIMENTAL
Intervention: All three aspirin doses
Number of subjects: 128
Study 15471991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 11697842 — intervention group
Group type: EXPERIMENTAL
Intervention: E7070 at 200 mg/m2/day
Number of subjects: 33
Study 11697842 — intervention group
Group type: EXPERIMENTAL
Intervention: E7070 at 160 mg/m2/day
Number of subjects: 33
Study 11697842 — intervention group
Group type: EXPERIMENTAL
Intervention: E7070 at 130 mg/m2/day
Number of subjects: 33
Study 11697842 — intervention group
Group type: EXPERIMENTAL
Intervention: E7070 (various doses)
Number of subjects: 33
Study 9593027 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg twice daily for 3 weeks)
Number of subjects: 8
Study 9593027 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg twice daily for 12 months)
Number of subjects: 8
Study 9593027 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 8
Study 7930727 — intervention group
Group type: EXPERIMENTAL
Intervention: Fc gamma RIIa‐H/H131 phenotype
Number of subjects: 48
Study 7930727 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization with pneumococcal vaccine
Number of subjects: 48
Study 3294594 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg three times a day)
Number of subjects: 0
Study 3294594 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg three times a day) + Nifedipine (20 mg tablet twice a day)
Number of subjects: 0
Study 3294594 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg tablet twice a day)
Number of subjects: 0
Study 3294594 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg tablet twice a day) + Captopril (25 mg three times a day)
Number of subjects: 0
Study 30354904 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-Care (POC) CRP testing
Number of subjects: 2844
Study 30354904 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal CRP levels
Number of subjects: 2844
Study 30354904 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated CRP levels
Number of subjects: 2844
Study 27366817 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-step advancement with FMA
Number of subjects: 34
Study 27366817 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise advancement with FMA
Number of subjects: 34
Study 26616119 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in use of the taxonomy (1‐day workshops and distance group tutorials)
Number of subjects: 400
Study 26616119 — intervention group
Group type: EXPERIMENTAL
Intervention: BCTTv1 (Behaviour Change Technique Taxonomy version 1)
Number of subjects: 400
Study 26616119 — intervention group
Group type: EXPERIMENTAL
Intervention: Training methods
Number of subjects: 400
Study 26616119 — intervention group
Group type: EXPERIMENTAL
Intervention: BCTTv1 for reporting descriptions of observed interventions
Number of subjects: 400
Study 24511883 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives
Number of subjects: 140
Study 24511883 — intervention group
Group type: COMPARATOR
Intervention: Control (no financial rewards)
Number of subjects: 140
Study 20513050 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone-impregnated bioresorbable dressing (Nasopore)
Number of subjects: 19
Study 20513050 — intervention group
Group type: COMPARATOR
Intervention: Saline-impregnated dressing
Number of subjects: 19
Study 17889863 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose acetylsalicylic acid (aspirin)
Number of subjects: 10
Study 17889863 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 10
Study 15673801 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 180
Study 15673801 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 180
Study 12548189 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic endometrial resection
Number of subjects: 181
Study 12548189 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic supracervical hysterectomy
Number of subjects: 181
Study 12548189 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 181
Study 10389557 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous lignocaine
Number of subjects: 166
Study 10389557 — intervention group
Group type: COMPARATOR
Intervention: No local anaesthetic (Control)
Number of subjects: 166
Study 8550787 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human GH (0.02 mg/kg BW.day, sc)
Number of subjects: 18
Study 8550787 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 18
Study 1990744 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency PTCA
Number of subjects: 89
Study 1990744 — intervention group
Group type: COMPARATOR
Intervention: Delayed PTCA (18 to 48 hours)
Number of subjects: 89
Study 1990744 — intervention group
Group type: EXPERIMENTAL
Intervention: Ineffective reperfusion (greater than 90% stenosis)
Number of subjects: 89
Study 1990744 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual lumen less than 0.4 mm after thrombolysis
Number of subjects: 89
Study 1990744 — intervention group
Group type: COMPARATOR
Intervention: Greater than 90% stenosis
Number of subjects: 89
Study 6308965 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (CTX)
Number of subjects: 58
Study 6308965 — intervention group
Group type: COMPARATOR
Intervention: Combination of ampicillin, methicillin, and netilmicin (AMN)
Number of subjects: 58
Study 30773174 — intervention group
Group type: EXPERIMENTAL
Intervention: Flank/abdominal radiotherapy
Number of subjects: 149
Study 30773174 — intervention group
Group type: COMPARATOR
Intervention: No flank/abdominal radiotherapy
Number of subjects: 149
Study 30773174 — intervention group
Group type: EXPERIMENTAL
Intervention: One reason to be stage III
Number of subjects: 149
Study 30773174 — intervention group
Group type: COMPARATOR
Intervention: Two or three reasons to be stage III
Number of subjects: 149
Study 28731928 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious game (Staying Alive)
Number of subjects: 82
Study 28731928 — intervention group
Group type: COMPARATOR
Intervention: Online course (PowerPoint lecture)
Number of subjects: 82
Study 25846344 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 6 mg·kg(‐1) preoperatively, followed by 3 mg·kg(‐1) twice daily for five doses
Number of subjects: 282
Study 25846344 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 282
Study 25846344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study 23078753 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary sinus lifting with autogenous bone augmentation and implant insertion at 6 months post grafting (Group I)
Number of subjects: 15
Study 23078753 — intervention group
Group type: COMPARATOR
Intervention: Maxillary sinus lifting with autogenous bone augmentation mixed with PRP (Group II)
Number of subjects: 15
Study 22048171 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of 20/20F at Months 0,6 (n=240)
Number of subjects: 1000
Study 22048171 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of 40/40F at Months 0,6 (n=241)
Number of subjects: 1000
Study 22048171 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of 40/40F at Months 0,2 (n=240)
Number of subjects: 1000
Study 22048171 — intervention group
Group type: COMPARATOR
Intervention: 3 doses of 20/20F at Months 0,1,6 (licensed schedule, n=239)
Number of subjects: 1000
Study 19537094 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavir (monotherapy for chronic TBE; n = 30)
Number of subjects: 143
Study 19537094 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavir (combined therapy for acute TBE; n = 113)
Number of subjects: 143
Study 17854480 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 143
Study 17854480 — intervention group
Group type: COMPARATOR
Intervention: Usual General Practitioner (GP) care
Number of subjects: 143
Study 15219658 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia
Number of subjects: 12
Study 15219658 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 12
Study 11478545 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Decision Group (n = 41)
Number of subjects: 114
Study 11478545 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon Decision Group (n = 39)
Number of subjects: 114
Study 11478545 — intervention group
Group type: COMPARATOR
Intervention: Advised to undergo mastectomy (n = 34)
Number of subjects: 114
Study 9553318 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women with PGDM
Number of subjects: 251
Study 9553318 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women with GDM
Number of subjects: 251
Study 9553318 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood of fetuses from PGDM and GDM mothers
Number of subjects: 251
Study 9553318 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-diabetic pregnant women)
Number of subjects: 251
Study 9553318 — intervention group
Group type: EXPERIMENTAL
Intervention: All study groups
Number of subjects: 251
Study 7996212 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotaped vignette with PPE
Number of subjects: 62
Study 7996212 — intervention group
Group type: COMPARATOR
Intervention: Videotaped vignette without PPE (Control)
Number of subjects: 62
Study 7996212 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PPE and NO PPE)
Number of subjects: 62
Study 3052153 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 0
Study 3052153 — intervention group
Group type: COMPARATOR
Intervention: Naloxone
Number of subjects: 0
Study 3052153 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 0
Study 31702625 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced assistant group
Number of subjects: 331
Study 31702625 — intervention group
Group type: COMPARATOR
Intervention: Inexperienced assistant group
Number of subjects: 331
Study 31702625 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 331
Study 28245914 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum dressing
Number of subjects: 90
Study 28245914 — intervention group
Group type: COMPARATOR
Intervention: Standard dressing (Control)
Number of subjects: 90
Study 25845448 — intervention group
Group type: EXPERIMENTAL
Intervention: Andolast 2 mg t.i.d.
Number of subjects: 549
Study 25845448 — intervention group
Group type: EXPERIMENTAL
Intervention: Andolast 4 mg t.i.d.
Number of subjects: 549
Study 25845448 — intervention group
Group type: EXPERIMENTAL
Intervention: Andolast 8 mg t.i.d.
Number of subjects: 549
Study 25845448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 549
Study 24579282 — intervention group
Group type: EXPERIMENTAL
Intervention: WITAUL distraction technique
Number of subjects: 160
Study 24579282 — intervention group
Group type: COMPARATOR
Intervention: Control method (deep breathing)
Number of subjects: 160
Study 21451140 — intervention group
Group type: EXPERIMENTAL
Intervention: α(1)-blocker (prazosin, 1 mg/20 kg body mass)
Number of subjects: 12
Study 21451140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 21451140 — intervention group
Group type: EXPERIMENTAL
Intervention: α(1)-blocker (prazosin)
Number of subjects: 12
Study 18458361 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports beans
Number of subjects: 16
Study 18458361 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports drink
Number of subjects: 16
Study 18458361 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel
Number of subjects: 16
Study 18458361 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 16
Study 16475496 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% cream
Number of subjects: 74
Study 16475496 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 74
Study 12656931 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 12656931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10638377 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate (CHO) diet for 2 days
Number of subjects: 8
Study 10638377 — intervention group
Group type: COMPARATOR
Intervention: Low carbohydrate (CHO) diet for 2 days
Number of subjects: 8
Study 8746332 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterol-enriched fraction from canola oil
Number of subjects: 21
Study 8746332 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 21
Study 8746332 — intervention group
Group type: EXPERIMENTAL
Intervention: Canola oil
Number of subjects: 21
Study 8746332 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 21
Study 8746332 — intervention group
Group type: EXPERIMENTAL
Intervention: Other lipids tested (petrolatum, fish oil, borage oil, sunflower seed oil, shea butter, fractions of unsaponifiable lipids from canola oil and shea butter)
Number of subjects: 21
Study 1539466 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant B subunit-whole cell cholera vaccine
Number of subjects: 0